<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230627058604N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-26</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Triparatide in dry socket and pain</public_title>
      <acronym></acronym>
      <scientific_title>The effect of using gelatin sponges impregnated with Triparatide on the incidence of dry socket and pain intensity after tooth extraction</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72540</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Blinding description: Two containers A and B are marked by the health personnel (the second supervisor of the thesis) that there is normal saline in one and the desired drug in the other. Without knowing the container containing the drug, the main researcher and the executive and the evaluator dipped each of the gelatin sponges in two different containers and placed them in the place of the two extracted teeth on both sides of the participant (for example, solution A is always on the left side of the participant, and solution B is placed on the right side of the patient.) Data analysis and drug effect evaluation are done after the completion of clinical procedures and notification of the principal investigator.</study_design>
      <phase>3</phase>
      <hc_freetext>Pain and incidence of dry socket after tooth extraction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: On the side of the intervention (for example, the right side of the patient) and the place of the extracted tooth, a gelatin sponge immersed for 8 minutes in Triparatide solution 250 mcg/2.4 mL belonging to Sina Pharmaceutical Company was placed and a figur of eight suture will be applied and by VAS and objective observation of pain and occurrence of dry socket. It is evaluated at intervals of  24-72 hours and one week after tooth extraction. Please note that due to the split mouth study, the other side of the patient will be considered as the control group, and normal saline is used instead of Triparatide. Intervention 2: Considering the split mouth of the other side of the mouth study will be considered as the control group and normal saline will be used instead of triparatide and in double-blind conditions, which will be done in the same way as the intervention side and subsequent examinations.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Investigating the effect of triparatide solution on the amount of pain and incidence of dry socket after tooth extraction and all data, including entry and exit criteria, implementation method, study results and documentation, and information of participating patients in a non-identifiable condition with ethical indicators.

When:
Beginning the access period since mid 2024

To whom:
Due to the need for skill and scientific information in the use of triparatide solution and the ability to make clinical judgment for its use, it will be available only to researchers working in academic and scientific institutions.

Conditions:
Use for systematic review studies
Use for clinical strategy
Use for retrospective studies
Use to conduct similar studies with a new approach

Where to obtain:
Vice President of Research and Technology of Tabriz University of Medical Sciences

How to obtain:
Calling via email or visiting in person to the Vice President of Research and Technology of Tabriz University of Medical Sciences and requesting the use of documents according to the mentioned conditions.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farzin Ahmadpour Pournaki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz / Golgasht St. / Tabriz University of Medical Sciences, Central Building No. 2 / Third Floor, Research and Technology Vice-Chancellor</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5145855359</zip>
        <telephone>+98 41 3236 7155</telephone>
        <email>phoenixinfire@ymail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farzin Ahmadpour Pournaki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz / Golgasht St. / Tabriz University of Medical Sciences, Central Building No. 2 / Third Floor, Research and Technology Vice-Chancellor</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5145855359</zip>
        <telephone>+98 41 3236 7155</telephone>
        <email>phoenixinfire@ymail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patients with an indication for the extraction of lower molar teeth bilaterally (split mouth)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Peri apical lesions
Poor oral hygiene
Smoking
Alcoholism
Diabetes
Hyper tension (stg 2 =&lt;)
Other systemic disease
Cancerous
Pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: On the side of the intervention (for example, the right side of the patient) and the place of the extracted tooth, a gelatin sponge immersed for 8 minutes in Triparatide solution 250 mcg/2.4 mL belonging to Sina Pharmaceutical Company was placed and a figur of eight suture will be applied and by VAS and objective observation of pain and occurrence of dry socket. It is evaluated at intervals of  24-72 hours and one week after tooth extraction. Please note that due to the split mouth study, the other side of the patient will be considered as the control group, and normal saline is used instead of Triparatide.</i_keyword>
      <i_keyword>Considering the split mouth of the other side of the mouth study will be considered as the control group and normal saline will be used instead of triparatide and in double-blind conditions, which will be done in the same way as the intervention side and subsequent examinations.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Dry socket. Timepoint: 24hours, 72hours and one week after extraxtion. Method of measurement: VAS (Visual Analysis System) and objective examination.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-09-10</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical sciences</contact_name>
        <contact_address>No. 144, Shahid Chamran alley, Mofatteh ave Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
